Parkin paves the path to antitumor immunity: Expanding Parkin’s role as a tumor suppressor

Parkin, a ring-between-ring-type E3 ubiquitin ligase, first shown to play a critical role in autosomal recessive juvenile Parkinsonism, has recently emerged as a key player in cancer biology. Parkin is now known to serve as a tumor suppressor, and its deregulation frequently promotes tumorigenesis....

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	The Journal of clinical investigation Ročník 134; číslo 22; s. 1 - 3
Hlavní autori:	Kim, Hyungsoo, Ronai, Ze’ev A.
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States American Society for Clinical Investigation 15.11.2024
Predmet:	Animals Cancer Cancer therapies Care and treatment CD8-Positive T-Lymphocytes - immunology Cell cycle Deregulation Development and progression Epigenetics Health aspects Humans Immune response Immunity (Disease) Inflammation Interferon Ligases Lymphocytes Metabolism Metastasis Mice Motility Mutation Neoplasms - genetics Neoplasms - immunology Parkin protein Parkinson's disease Quality control T cells Tumor suppressor genes Tumor Suppressor Proteins - genetics Tumor Suppressor Proteins - immunology Tumor Suppressor Proteins - metabolism Ubiquitin-Protein Ligases - genetics Ubiquitin-Protein Ligases - immunology Ubiquitin-Protein Ligases - metabolism
ISSN:	1558-8238, 0021-9738, 1558-8238
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Popis
Shrnutí:	Parkin, a ring-between-ring-type E3 ubiquitin ligase, first shown to play a critical role in autosomal recessive juvenile Parkinsonism, has recently emerged as a key player in cancer biology. Parkin is now known to serve as a tumor suppressor, and its deregulation frequently promotes tumorigenesis. In this issue of the JCI, Perego et al. expand that role by showing that Parkin expression stimulated an interferon (IFN) response to modulate CD8+ T cell activity. These findings suggest that, in addition to directly inhibiting tumor progression, Parkin enhances antitumor immune responses, highlighting it as a promising therapeutic target for cancer treatment.
Bibliografia:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23
ISSN:	1558-8238 0021-9738 1558-8238
DOI:	10.1172/JCI185838